1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. Qiagen N.V.
  6. News
  7. Summary
    QGEN   NL0012169213

QIAGEN N.V.

(QGEN)
  Report
Delayed Nyse  -  04:01 2022-06-24 pm EDT
46.63 USD   +4.02%
06/23Qiagen N.V. to Seek M&A
CI
06/23TRANSCRIPT : Qiagen N.V. - Shareholder/Analyst Call
CI
06/17TCS Partners with QIAGEN in Driving its Cloud Transformation Strategy
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

QIAGEN NV : Berenberg keeps its Buy rating

05/16/2022 | 07:37am EDT

Berenberg analyst Odysseas Manesiotis maintains his Buy rating on the stock. The target price remains unchanged at EUR 50.


© MarketScreener with dpa-AFX Analyser 2022
All news about QIAGEN N.V.
06/23Qiagen N.V. to Seek M&A
CI
06/23TRANSCRIPT : Qiagen N.V. - Shareholder/Analyst Call
CI
06/17TCS Partners with QIAGEN in Driving its Cloud Transformation Strategy
AQ
06/16Tata Consultancy Services Bags New Contract from Germany's QIAGEN
MT
06/10QIAGEN N.V. : Notification and public disclosure of transactions by persons
EQ
06/08QIAGEN NV : Jefferies reaffirms its Neutral rating
MD
06/08TRANSCRIPT : QIAGEN N.V. Presents at 2022 Jefferies Global Healthcare Conference, Jun-08-2..
CI
06/03Test makers target monkeypox market as cases surge
RE
06/01U.S. CDC Endorses the Use of Digital PCR Technology for Wastewater Surveillance of Infe..
BU
05/26QIAGEN NV : Gets a Buy rating from Deutsche Bank
MD
More news
Analyst Recommendations on QIAGEN N.V.
More recommendations
Financials (USD)
Sales 2022 2 093 M - -
Net income 2022 387 M - -
Net Debt 2022 497 M - -
P/E ratio 2022 27,3x
Yield 2022 -
Capitalization 10 606 M 10 606 M -
EV / Sales 2022 5,31x
EV / Sales 2023 4,97x
Nbr of Employees 6 000
Free-Float 98,2%
Chart QIAGEN N.V.
Duration : Period :
Qiagen N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends QIAGEN N.V.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Last Close Price 46,63 $
Average target price 56,32 $
Spread / Average Target 20,8%
EPS Revisions
Managers and Directors
Thierry Bernard Chief Executive Officer & Managing Director
Roland Sackers Vice President-Finance
Lawrence A. Rosen Chairman-Supervisory Board
Barthold Piening Senior Vice President & Head-Global Operations
Lezette Young Manager-Compliance & Legal
Sector and Competitors
1st jan.Capi. (M$)
QIAGEN N.V.-19.34%9 965
MODERNA, INC.-43.59%54 123
IQVIA HOLDINGS INC.-25.02%38 185
LONZA GROUP AG-35.92%38 059
SEAGEN INC.12.55%31 230
ALNYLAM PHARMACEUTICALS, INC.-13.73%17 102